Review Article
To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients
Table 3
Major factors impacting decision making in radioiodine remnant ablation, 2009 ATA guideline [
2].
|
Factors |
Description | Expected Benefit | | | Decreased risk of death | Decreased risk of recurrence | May facilitate initial staging and followup | RAI ablation usually recommended | Strength of evidence |
| T1 | ≤1 cm, intrathyroidal or microscopic multifocal | No | No | Yes | No | E | 1-2 cm, intrathyroidal | No | Conflicting data | Yes | Selective use | I | T2 | >2–4 cm, intrathyroidal | No | Conflicting data | Yes | Selective use | C | T3 | >4 cm, | | | | | | <45 years | No | Conflicting data | Yes | Yes | B | ≥45 years | Yes | Yes | Yes | Yes | B | Any size, any age, minimal extrathyroidal extension | No | Inadequate data | Yes | Selective use | I | T4 | Any size with gross extrathyroidal extension | Yes | Yes | Yes | Yes | B | NX, N0 | No metastatic nodes documented | No | No | Yes | No | I | N1 | <45 years | No | Conflicting data | Yes | Selective use | C | >45 years | Conflicting data | Conflicting data | Yes | Selective use | C | M1 | Distant metastases present | Yes | Yes | Yes | Yes | A |
|
|